The dipeptidyl peptidase-1 (DPP1) inhibitor brensocatib became the first licensed therapy for bronchiectasis in the USA and Europe in 2025,1 based on the phase 3 ASPEN trial showing an approximate 20% ...
Abstract: Music Performance Anxiety (MPA) is highly prevalent among musicians and often debilitating, associated with changes in cognitive, emotional, behavioral, and physiological responses to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results